HLTH Europe 2026 Highlights Rising Demand for GLP-1 Therapies as Coherent Market Insights Releases New Industry Outlook

Amsterdam, June 2026 – Healthcare leaders from across the world gathered at HLTH Europe 2026.to discuss the innovations and trends expected to shape the future of medicine. Among the organizations contributing to these conversations was Coherent Market Insights (CMI), which participated as an Official Partner and presented insights from its newly released GLP-1 Market Analysis (2026–2033) Executive Summary Report.

The four-day event, held at Amsterdam's RAI Convention Centre, attracted healthcare professionals, pharmaceutical companies, investors, technology providers, and policymakers representing more than 65 countries. Discussions focused on key industry priorities such as digital health, artificial intelligence, patient-centered care, healthcare accessibility, and pharmaceutical innovation.

One of the most talked-about subjects throughout the conference was the rapid expansion of GLP-1 receptor agonist therapies and their growing influence on metabolic healthcare.

GLP-1 Treatments Gain Attention Across the Healthcare Ecosystem

Over the past few years, GLP-1 therapies have evolved from specialized diabetes treatments into a broader category with applications in weight management and metabolic health. This shift has generated considerable interest among healthcare providers, pharmaceutical manufacturers, investors, and public health organizations.

To help stakeholders better understand the opportunities emerging within this market, Coherent Market Insights introduced a detailed industry assessment covering market performance, competitive developments, growth drivers, and future outlook.

According to the report, the global GLP-1 market generated approximately USD 53.5 billion in revenue during 2025. Continued demand and ongoing innovation are expected to drive substantial growth, with market value projected to reach nearly USD 102.4 billion by 2031. Long-term forecasts indicate that the wider GLP-1 receptor agonist segment could surpass USD 311.6 billion by 2033.

Industry analysts attribute this expansion to increasing awareness of metabolic health challenges and the growing adoption of advanced treatment options.

Rising Health Challenges Support Market Growth

The prevalence of obesity and diabetes continues to rise worldwide, creating demand for more effective and scalable treatment solutions. Improved diagnosis rates, expanded healthcare coverage, and broader physician awareness are also contributing to increased utilization of GLP-1 therapies across multiple regions.

Participants at HLTH Europe frequently cited metabolic health as one of healthcare's most urgent priorities, highlighting the need for innovative approaches capable of delivering meaningful clinical outcomes.

As healthcare systems focus more heavily on preventive care and long-term disease management, therapies addressing obesity-related and metabolic conditions are expected to play an increasingly important role.

Advancing Patient-Centric Innovation

Competition within the GLP-1 market is encouraging pharmaceutical companies to develop solutions that not only improve efficacy but also enhance patient convenience and treatment adherence.

Current innovation efforts include oral formulations, extended-duration therapies, and combination treatments designed to address multiple metabolic pathways. These advancements could improve accessibility while making long-term treatment management easier for patients.

Experts believe such developments will help expand the reach of GLP-1 therapies and support broader adoption in both established and emerging healthcare markets.

Market Intelligence Becomes Increasingly Valuable

The discussions at HLTH Europe 2026 also underscored the growing importance of reliable market research in supporting strategic healthcare decisions. As industry dynamics evolve, organizations are seeking accurate data and forward-looking analysis to identify opportunities, evaluate risks, and guide investment strategies.

Through ongoing research and industry engagement, Coherent Market Insights continues to provide market intelligence across healthcare, life sciences, technology, and industrial sectors.

Its participation at HLTH Europe reflects a broader commitment to supporting informed decision-making and fostering conversations around the future of healthcare innovation.

The company's latest GLP-1 Market Analysis (2026–2033) Executive Summary Report is now available for industry stakeholders seeking deeper insights into one of healthcare's fastest-growing therapeutic categories.

Business inquiries and report access:
[email protected]

About Coherent Market Insights

Coherent Market Insights is a global market research and consulting firm providing comprehensive analysis across healthcare, pharmaceuticals, technology, industrial markets, and consumer industries. The company delivers data-driven insights that help organizations understand market trends, evaluate opportunities, and make informed strategic decisions in an evolving global business environment.

https://www.coherentmarketinsights.com/